Bibliography
- Cavero I, Crumb W. Safety Pharmacology Society: 5th annual meeting, 27 – 29 September 2005, Mannheim, Germany. Expert Opin Drug Saf 2006;5:181-5
- Cavero I. Safety Pharmacology Society: 6th annual meeting 26 – 28 September 2006, San Diego, USA. Expert Opin Drug Saf 2007;6:87-92
- Cavero I. Safety Pharmacology Society: 7th annual meeting 19 – 20 September 2007, Edinburgh, UK. Expert Opin Drug Saf 2008;7:91-100
- Cavero I. Safety Pharmacology Society: 8th annual meeting 22 – 25 September 2008, Madison, USA. Expert Opin Drug Saf 2009;8:1-11
- Cavero I. Safety Pharmacology Society: 9th annual meeting 15 – 18 September 2009, Strasbourg, France. Expert Opin Drug Saf 2010;9:365-78
- Langer R. Biomaterials for drug delivery and tissue engineering. MRS Bulletin 2006;31:477-85
- Langer R. A conversation with Robert Langer: pioneering biomedical scientist and engineer. Interview by Paul S. Weiss. ACS Nano 2009;3:756-61
- ICH Harmonised Tripartite Guideline. Safety pharmacology studies for human pharmaceuticals S7A. 2000. Available from: www.ich.org/LOB/media/MEDIA504.pdf
- ICH Harmonised Tripartite Guideline. The non-clinical evaluation of the potential for delayed ventricular repolarization (QT interval prolongation) by human pharmaceuticals. S7B. 2005. Available from: www.ich.org/LOB/media/MEDIA2192.pdf
- ICH harmonised tripartite guideline preclinical safety evaluation of biotechnology-derived pharmaceuticals S6. Available from: www.ich.org/LOB/media/MEDIA503.pdf
- ICH harmonised tripartite guideline nonclinical evaluation for anticancer pharmaceuticals S9. Available from: www.ich.org/LOB/media/MEDIA5785.pdf
- ICH Harmonised Tripartite Guideline. E14: the clinical evaluation of QT/QTc interval prolongation and proarrhythmic potential for non-antiarrhythmic drugs (2005). Available from: www.ich.org/LOB/media/MEDIA1476.pdf
- Heist EK, Ruskin JN. Drug-induced arrhythmia. Circulation 2010;122:1426-35
- Kaitin KI. Deconstructing the drug development process: the new face of innovation. Clin Pharmacol Ther 2010;87:356-61
- Kaitin KI. Obstacles and opportunities in new drug development. Clin Pharmacol Ther 2008;83:210-12
- Guidance for industry in vivo drug metabolism/drug interaction studies. Study design, data analysis, and recommendations for dosing and labelling. Available from: www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/ucm072119.pdf
- Food and Drug Administration, HHS. New drug and biological drug products; evidence needed to demonstrate effectiveness of new drugs when human efficacy studies are not ethical or feasible. Final rule. Fed Regist 2002;67:37988-98
- Matthews EJ, Frid AA. Prediction of drug-related cardiac adverse effects in humans-A: creation of a database of effects and identification of factors affecting their occurrence. Regul Toxicol Pharmacol 2010;56:247-75
- Frid AA, Matthews EJ. Prediction of drug-related cardiac adverse effects in humans-B: use of QSAR programs for early detection of drug-induced cardiac toxicities. Regul Toxicol Pharmacol 2010;56:276-89
- Guidance for Industry Assessment of Abuse Potential of Drugs. Draft guidance. Available from: www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/UCM198650.pdf
- Guidance for Industry. Animal models - Essential elements to address efficacy under the Animal Rule. Available from: http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/UCM078923
- Cavero I. Exploratory safety pharmacology: a new safety paradigm to de-risk drug candidates prior to selection for regulatory science investigations. Expert Opin Drug Saf 2009;8:627-47
- Regan CP, Cresswell HK, Zhang R, Novel method to assess cardiac electrophysiology in the rat: characterization of standard ion channel blockers. J Cardiovasc Pharmacol 2005;46:68-75
- Lynch JJ Jr, Stump GL, Kane SA, The prototype serotonin 5-HT1B/1D agonist sumatriptan increases the severity of myocardial ischemia during atrial pacing in dogs with coronary artery stenosis. J Cardiovasc Pharmacol 2009;53:474-9
- Lynch JJ, Shen YT, Pittman TJ, Effects of the prototype serotonin 5-HT(1B/1D) receptor agonist sumatriptan and the calcitonin gene-related peptide (CGRP) receptor antagonist CGRP(8-37) on myocardial reactive hyperemic response in conscious dogs. Eur J Pharmacol 2009;623:96-102
- Regan CP, Stump GL, Kane SA, Calcitonin gene-related peptide receptor antagonism does not affect the severity of myocardial ischemia during atrial pacing in dogs with coronary artery stenosis. J Pharmacol Exp Ther 2009;328:571-8
- Easter A, Bell ME, Damewood JR Jr, Approaches to seizure risk assessment in preclinical drug discovery. Drug Discov Today 2009;14:876-84
- Cavero I. Cardiovascular system assessment best practices: a Safety Pharmacology Society meeting. Expert Opin Drug Saf 2010;9:855-66
- Liebelt EL. The specialty of medical toxicology: beyond poisonous arrows and activated charcoal. Clin Pharmacol Ther 2010;88:298-301
- Guidance for industry diabetes mellitus: developing drugs and therapeutic biologics for treatment and prevention. Draft guidance. Available from: www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/ucm071624.pdf
- Cavero I, Crumb W. ICH S7B draft guideline on the non-clinical strategy for testing delayed cardiac repolarisation risk of drugs: a critical analysis. Expert Opin Drug Saf 2005;4:509-30
- Committee on Toxicity Testing and Assessment of Environmental Agents, National Research Council. Toxicity Testing in the 21st Century: a Vision and a strategy. The National Academic Press. 2007. Available from: www.nap.edu/openbook.php?record_id=11970&page=1
- Critical Path Opportunities Report. FDA 2006. Available from: www.fda.gov/oc/initiatives/criticalpath/reports/opp_report.pdf
- Williams M. Productivity shortfalls in drug discovery: contributions from the preclinical sciences? J Pharmacol Exp Ther 2011;336:3-825
- Available from: http://phmtox.msu.edu/education/onlinepsm.html